AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 1959004 — intervention group
Group type: EXPERIMENTAL
Intervention: Both oxerutins and placebo (compliance with tablets and stockings)
Number of subjects: 138
Study 7325407 — intervention group
Group type: EXPERIMENTAL
Intervention: Cinnarizine
Number of subjects: 37
Study 7325407 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil
Number of subjects: 37
Study 30887623 — intervention group
Group type: EXPERIMENTAL
Intervention: Some family involvement in home-based care
Number of subjects: 0
Study 28520962 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative 1-week systematic high-intensity inpatient exercise regimen
Number of subjects: 101
Study 28520962 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard preoperative care)
Number of subjects: 101
Study 26573188 — intervention group
Group type: EXPERIMENTAL
Intervention: Entecavir (0.5 mg/day, oral)
Number of subjects: 90
Study 26573188 — intervention group
Group type: COMPARATOR
Intervention: Adefovir (10 mg/day, oral)
Number of subjects: 90
Study 23102599 — intervention group
Group type: EXPERIMENTAL
Intervention: High titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Number of subjects: 748
Study 23102599 — intervention group
Group type: COMPARATOR
Intervention: Low titer of IgG antibodies to malondialdehyde modified oxidized low-density lipoproteins (oxLDLAbs)
Number of subjects: 748
Study 21615790 — intervention group
Group type: EXPERIMENTAL
Intervention: Colonoscopy-first group (n = 87)
Number of subjects: 176
Study 21615790 — intervention group
Group type: COMPARATOR
Intervention: EGD-first group (n = 89)
Number of subjects: 176
Study 21615790 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 176
Study 19055285 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral Yongquan (KI 1) application with Biyankang Tablet, once each night
Number of subjects: 125
Study 19055285 — intervention group
Group type: COMPARATOR
Intervention: 0.5% Ephedrine naristillae, one drop each nose each time, tid
Number of subjects: 125
Study 16873326 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral balanced splint
Number of subjects: 57
Study 16873326 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine guidance splint
Number of subjects: 57
Study 16873326 — intervention group
Group type: COMPARATOR
Intervention: Nonoccluding splint
Number of subjects: 57
Study 12591005 — intervention group
Group type: EXPERIMENTAL
Intervention: Borage oil 3000 mg daily
Number of subjects: 30
Study 12591005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 3000 mg daily
Number of subjects: 30
Study 12591005 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil 1500 mg and borage oil 1500 mg daily
Number of subjects: 30
Study 12591005 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 11045840 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling plus 628 +/- 254 mL of an energy supplement rich in fat (31% of energy) and linoleic acid (16% of energy) for 3 months
Number of subjects: 36
Study 11045840 — intervention group
Group type: COMPARATOR
Intervention: Intensive dietary counseling only
Number of subjects: 36
Study 8716526 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of a jaundice meter to validate nurses' visual assessments
Number of subjects: 0
Study 8716526 — intervention group
Group type: COMPARATOR
Intervention: Visual assessments by nurses
Number of subjects: 0
Study 1462745 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective intestinal decontamination (3 oral nonabsorbable antibiotics: Neomycin 1 gr, Colistin 1.500.000 U, Nystatin 1.000.000 U every 6 hours for first 74 patients; Norfloxacin 400 mg BID for following patients) for at least 5 days
Number of subjects: 94
Study 1462745 — intervention group
Group type: COMPARATOR
Intervention: Not treated (control group)
Number of subjects: 94
Study 6239538 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose chlorozotocin (120 mg/m2 if untreated, 100 mg/m2 if treated)
Number of subjects: 78
Study 6239538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chlorozotocin (200 mg/m2 if untreated, 175 mg/m2 if treated)
Number of subjects: 78
Study 6239538 — intervention group
Group type: COMPARATOR
Intervention: Low-dose and high-dose chlorozotocin
Number of subjects: 78
Study 6239538 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose chlorozotocin
Number of subjects: 78
Study 30828982 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavy resistance training for 12 weeks
Number of subjects: 29
Study 30828982 — intervention group
Group type: COMPARATOR
Intervention: Untrained controls
Number of subjects: 29
Study 30828982 — intervention group
Group type: EXPERIMENTAL
Intervention: Young men (19-27 years), n = 9
Number of subjects: 29
Study 30187978 — intervention group
Group type: EXPERIMENTAL
Intervention: Varenicline (0.5 mg for 1 week, then 1 mg for 11 weeks, twice daily)
Number of subjects: 510
Study 30187978 — intervention group
Group type: COMPARATOR
Intervention: Placebo (identical unlabelled tablets for 12 weeks)
Number of subjects: 510
Study 28423165 — intervention group
Group type: EXPERIMENTAL
Intervention: League tables
Number of subjects: 221
Study 28423165 — intervention group
Group type: COMPARATOR
Intervention: Funnel plots
Number of subjects: 221
Study 26242048 — intervention group
Group type: EXPERIMENTAL
Intervention: Qilin Pills (6 g, tid) combined with clomiphene (50 mg, qd)
Number of subjects: 300
Study 26242048 — intervention group
Group type: COMPARATOR
Intervention: Clomiphene (50 mg, qd) alone
Number of subjects: 300
Study 23482340 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (methotrexate injection alone)
Number of subjects: 406
Study 23482340 — intervention group
Group type: COMPARATOR
Intervention: Conservative surgery with post-operative methotrexate injection
Number of subjects: 406
Study 23482340 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative surgery
Number of subjects: 406
Study 23482340 — intervention group
Group type: COMPARATOR
Intervention: Radical surgery
Number of subjects: 406
Study 20586147 — intervention group
Group type: EXPERIMENTAL
Intervention: Polarized light (PL) applied to neuropathic ulcers of diabetic foot twice daily for ten minutes for three months
Number of subjects: 59
Study 20586147 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidants (60 mg hydrosoluble CoQ10, 100 mg alpha‐lipoic acid (ALA), and 200 mg vitamin E) used in two daily doses for three months
Number of subjects: 59
Study 20586147 — intervention group
Group type: EXPERIMENTAL
Intervention: Simultaneous application of PL and antioxidants
Number of subjects: 59
Study 18818788 — intervention group
Group type: EXPERIMENTAL
Intervention: Liver stiffness measurement (LSM) by transient elastography with a cut-off value of 15.9 kPa for cirrhosis determination
Number of subjects: 386
Study 18818788 — intervention group
Group type: EXPERIMENTAL
Intervention: High LSM group (LSM ≥ 15.9 kPa)
Number of subjects: 386
Study 18818788 — intervention group
Group type: COMPARATOR
Intervention: Low LSM group (LSM < 15.9 kPa)
Number of subjects: 386
Study 16785773 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 64
Study 16785773 — intervention group
Group type: COMPARATOR
Intervention: Placebo intervention
Number of subjects: 64
Study 12753150 — intervention group
Group type: EXPERIMENTAL
Intervention: famotidine
Number of subjects: 7
Study 12753150 — intervention group
Group type: COMPARATOR
Intervention: ranitidine
Number of subjects: 7
Study 12476494 — intervention group
Group type: EXPERIMENTAL
Intervention: Fränkel function regulators
Number of subjects: 51
Study 12476494 — intervention group
Group type: EXPERIMENTAL
Intervention: Harvold activators
Number of subjects: 51
Study 12476494 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 51
Study 9084355 — intervention group
Group type: EXPERIMENTAL
Intervention: Audiovisual erotic stimulation
Number of subjects: 17
Study 9084355 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with audiovisual erotic stimulation
Number of subjects: 17
Study 9084355 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual genital stimulation with distracting task
Number of subjects: 17
Study 9084355 — intervention group
Group type: EXPERIMENTAL
Intervention: Masturbation
Number of subjects: 17
Study 8263331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraperitoneal drains
Number of subjects: 200
Study 8263331 — intervention group
Group type: COMPARATOR
Intervention: No drains (Control)
Number of subjects: 200
Study 3979007 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (0.075 mg/kg three times a day)
Number of subjects: 12
Study 3979007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3979007 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release theophylline (10 mg/kg twice a day)
Number of subjects: 12
Study 31509896 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen (HBO2) therapy
Number of subjects: 54
Study 31509896 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibular free flap reconstruction
Number of subjects: 54
Study 31509896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline, Vitamin E, and sometimes a bisphosphonate
Number of subjects: 54
Study 29708281 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022 (single ascending doses of 10, 30, 100, 300, 1000 or 1300 mg; multiple ascending doses of 100, 300 or 1000 mg day-1 for 7 days)
Number of subjects: 0
Study 29708281 — intervention group
Group type: EXPERIMENTAL
Intervention: OBE022
Number of subjects: 0
Study 29708281 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26965178 — intervention group
Group type: EXPERIMENTAL
Intervention: CaHMB, vitamin D, and protein supplementation
Number of subjects: 75
Study 26965178 — intervention group
Group type: COMPARATOR
Intervention: Standard postoperative nutrition
Number of subjects: 75
Study 24708640 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (600 mg) and magnesium (200 mg)
Number of subjects: 0
Study 24708640 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22374888 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelfoam soaked with HA-CMC
Number of subjects: 287
Study 22374888 — intervention group
Group type: COMPARATOR
Intervention: Gelfoam only (Control)
Number of subjects: 287
Study 20346640 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 51
Study 20346640 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Standard Care (Control)
Number of subjects: 51
Study 20346640 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (CBT and Control)
Number of subjects: 51
Study 18414367 — intervention group
Group type: EXPERIMENTAL
Intervention: Parecoxib 40 mg
Number of subjects: 50
Study 18414367 — intervention group
Group type: COMPARATOR
Intervention: Ketorolac 30 mg
Number of subjects: 50
Study 16320092 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous-sound fMRI
Number of subjects: 16
Study 16320092 — intervention group
Group type: COMPARATOR
Intervention: Conventional fMRI
Number of subjects: 16
Study 16320092 — intervention group
Group type: EXPERIMENTAL
Intervention: Both scanning protocols
Number of subjects: 16
Study 12893153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular Hyalgan injections
Number of subjects: 38
Study 12893153 — intervention group
Group type: COMPARATOR
Intervention: Arthroscopic washout
Number of subjects: 38
Study 9895040 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 63
Study 9895040 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 9895040 — intervention group
Group type: COMPARATOR
Intervention: Placebo/expect alcohol
Number of subjects: 63
Study 7984193 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance
Number of subjects: 821
Study 7984193 — intervention group
Group type: COMPARATOR
Intervention: Standard insertion procedures (Control)
Number of subjects: 821
Study 7984193 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful catheterization
Number of subjects: 821
Study 7984193 — intervention group
Group type: EXPERIMENTAL
Intervention: Needle passes
Number of subjects: 821
Study 2603701 — intervention group
Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 50
Study 2603701 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 50
Study 1177792 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained release isosorbide dinitrate (Sorbidilat Retard)
Number of subjects: 0
Study 1177792 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30427251 — intervention group
Group type: COMPARATOR
Intervention: Cluster Set (CS) - 4 × [2 × 3], 30‐s intraset rest, 90‐s interset rest
Number of subjects: 8
Study 30427251 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Set (TS) - 4 × 6, 2‐min interset rest
Number of subjects: 8
Study 30427251 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint power produced at the hip during TS
Number of subjects: 8
Study 30427251 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint power produced at the hip during CS
Number of subjects: 8
Study 28600158 — intervention group
Group type: EXPERIMENTAL
Intervention: WLM plus lorcaserin
Number of subjects: 182
Study 28600158 — intervention group
Group type: COMPARATOR
Intervention: WLM plus placebo
Number of subjects: 182
Study 26164694 — intervention group
Group type: EXPERIMENTAL
Intervention: Group prenatal care (Centering Pregnancy Plus [CP+])
Number of subjects: 984
Study 26164694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 984
Study 22453307 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical elastic compression stocking
Number of subjects: 88
Study 22453307 — intervention group
Group type: COMPARATOR
Intervention: No stocking (control)
Number of subjects: 88
Study 20552100 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride exposure (Crest toothpaste 0.243% sodium fluoride and Equate rinse 0.05% sodium fluoride)
Number of subjects: 100
Study 20552100 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonfluoridated toothpaste (Tom's of Maine)
Number of subjects: 100
Study 20552100 — intervention group
Group type: COMPARATOR
Intervention: Control group (unused Ni-Ti wires)
Number of subjects: 100
Study 19276493 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel (300 mg bolus dose followed by 75 mg once daily)
Number of subjects: 0
Study 16822130 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential effects in the Simon task
Number of subjects: 0
Study 16822130 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive conflict
Number of subjects: 0
Study 16822130 — intervention group
Group type: EXPERIMENTAL
Intervention: Feature integration account
Number of subjects: 0
Study 12738811 — intervention group
Group type: EXPERIMENTAL
Intervention: SC‐51 (200 mg)
Number of subjects: 48
Study 12738811 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48
Study 10735263 — intervention group
Group type: EXPERIMENTAL
Intervention: Statistical concepts of significance and power used in determining sample size for trials.
Number of subjects: 0
Study 10735263 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster randomized trials design.
Number of subjects: 0
Study 1356467 — intervention group
Group type: EXPERIMENTAL
Intervention: Excision and primary suture
Number of subjects: 120
Study 1356467 — intervention group
Group type: COMPARATOR
Intervention: Excision and open packing
Number of subjects: 120
Study 3874897 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transhepatic variceal obliteration using stainless steel coils followed by 50% glucose and Gelfoam
Number of subjects: 63
Study 3874897 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective cases of transhepatic variceal obliteration
Number of subjects: 63
Study 3874897 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (control group)
Number of subjects: 63
Study 27532425 — intervention group
Group type: EXPERIMENTAL
Intervention: LEAP intervention
Number of subjects: 80
Study 27532425 — intervention group
Group type: COMPARATOR
Intervention: Psychoeducational control condition
Number of subjects: 80
Study 29331169 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐min step‐in‐place test (fitness test)
Number of subjects: 33
Study 29331169 — intervention group
Group type: COMPARATOR
Intervention: Control group (no fitness testing)
Number of subjects: 33
Study 27438754 — intervention group
Group type: EXPERIMENTAL
Intervention: Digital Health Intervention (DHI)
Number of subjects: 343
Study 27438754 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 343
Study 24874481 — intervention group
Group type: EXPERIMENTAL
Intervention: Overexpression of TBLR1 in Hela and Siha cell lines
Number of subjects: 0
Study 24874481 — intervention group
Group type: COMPARATOR
Intervention: RNAi-mediated knockdown of TBLR1
Number of subjects: 0
Study 24874481 — intervention group
Group type: EXPERIMENTAL
Intervention: TBLR1 expression levels
Number of subjects: 0
Study 23186118 — intervention group
Group type: EXPERIMENTAL
Intervention: School-led FRIENDS
Number of subjects: 41
Study 23186118 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-led FRIENDS
Number of subjects: 41
Study 23186118 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 41
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: Postprandial glucose excursions (AUC(ppg))
Number of subjects: 973
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: Total daytime glucose concentrations (AUC(total))
Number of subjects: 973
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: Percentage of glycaemia due to postprandial excursions (%(ppg))
Number of subjects: 973
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA‐IR
Number of subjects: 973
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: HOMA‐B
Number of subjects: 973
Study 20598608 — intervention group
Group type: EXPERIMENTAL
Intervention: ΔI30/ΔG30 ratio
Number of subjects: 973
Study 17122432 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral wrist splinting
Number of subjects: 63
Study 17122432 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended wrist splinting
Number of subjects: 63
Study 17122432 — intervention group
Group type: COMPARATOR
Intervention: Routine therapy (Control)
Number of subjects: 63
Study 16132802 — intervention group
Group type: COMPARATOR
Intervention: Dietary supplements
Number of subjects: 250
Study 16132802 — intervention group
Group type: COMPARATOR
Intervention: Dietary fat
Number of subjects: 250
Study 16132802 — intervention group
Group type: COMPARATOR
Intervention: Highest quartile of beef and pork intake
Number of subjects: 250
Study 16132802 — intervention group
Group type: COMPARATOR
Intervention: Fat intake
Number of subjects: 250
Study 12097764 — intervention group
Group type: EXPERIMENTAL
Intervention: Prulifloxacin 600 mg once daily for 10 days
Number of subjects: 235
Study 12097764 — intervention group
Group type: COMPARATOR
Intervention: Ciprofloxacin 500 mg twice a day for 10 days
Number of subjects: 235
Study 10023111 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,000 mg lysine-acetylsalicylic acid i.v.
Number of subjects: 56
Study 10023111 — intervention group
Group type: COMPARATOR
Intervention: 0.5 mg ergotamine s.c.
Number of subjects: 56
Study 7478833 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone phosphate 0.6 mg/kg/d (dexamethasone base 0.5 mg/kg/d)
Number of subjects: 209
Study 7478833 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 209
Study 1926256 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen
Number of subjects: 39
Study 1926256 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 39
Study 7049957 — intervention group
Group type: EXPERIMENTAL
Intervention: Erythromycin (2 X 1 g daily per os)
Number of subjects: 60
Study 7049957 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin (3 X 0.75 g daily per os)
Number of subjects: 60
Study 31134323 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral vinorelbine (60 mg/m2)
Number of subjects: 222
Study 31134323 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous vinorelbine (25 mg/m2)
Number of subjects: 222
Study 31134323 — intervention group
Group type: EXPERIMENTAL
Intervention: Population pharmacokinetic analysis (oral: n=222; intravenous: n=111)
Number of subjects: 222
Study 31134323 — intervention group
Group type: COMPARATOR
Intervention: Reference European data set (oral: 80 mg/m2; intravenous: 30 mg/m2)
Number of subjects: 222
Study 28237295 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate/low-GI diet (LGI, n = 31)
Number of subjects: 87
Study 28237295 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-carbohydrate/high-GI diet (HGI, n = 30)
Number of subjects: 87
Study 28237295 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF, n = 26)
Number of subjects: 87
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure
Number of subjects: 427
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximum urethral closure pressure
Number of subjects: 427
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Urinary NTx
Number of subjects: 427
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2
Number of subjects: 427
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 427
Study 27113967 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D2 plus D3
Number of subjects: 427
Study 27113967 — intervention group
Group type: COMPARATOR
Intervention: TOMUS subjects
Number of subjects: 427
Study 27113967 — intervention group
Group type: COMPARATOR
Intervention: ValUE subjects
Number of subjects: 427
Study 23624466 — intervention group
Group type: EXPERIMENTAL
Intervention: Multicomponent school-based intervention programme targeting physical activity, sedentary and dietary behaviours over 20 months
Number of subjects: 1324
Study 22386472 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg ABT-894 twice daily
Number of subjects: 404
Study 22386472 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg ABT-894 twice daily
Number of subjects: 404
Study 22386472 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg ABT-894 twice daily
Number of subjects: 404
Study 22386472 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg ABT-894 twice daily
Number of subjects: 404